Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of AT-527 on Digoxin PK in Healthy Adults
NCT05137626Phase 1Completed
- Sponsor
- Atea Pharmaceuticals
- Start
- Nov 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of bemnifosbuvir in coronavirus disease 2019 (COVID-19) and hepatitis C (HCV) (2 arms), sponsored by Atea Pharmaceuticals. Primary endpoints: Single-dose pharmacokinetics of digoxin alone at Day 1 and Single-dose pharmacokinetics of digoxin with AT-527 at Day 15. Started Nov 2021; status: completed.
02
Drugs
bemnifosbuvir
03
Conditions
coronavirus disease 2019 (COVID-19)hepatitis C (HCV)
Beyond the preview
Go deeper on NCT05137626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05137626.